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Background. Two major causes of gastric ulcers are Helicobacter pylori (H. pylori) infection and nonsteroidal anti-inﬂammatory
drug (NSAID) use. Aims. This study aimed to determine if there were diﬀerent expressions of matrix metalloproteinases (MMPs)
and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) between H. pylori-infected and NSAID-related ulcers. Methods.T h e
126 gastric ulcer patients (H. pylori infected n = 46; NSAID related n = 30; combined with two factors n = 50) provided ulcer
and nonulcer tissues for assessment of MMP-3, -7, and -9 and TIMP-1 expression by immunohistochemical staining. Results.
Gastric ulcer tissues had signiﬁcantly higher MMP-3, -7, and -9 and TIMP-1 expressions than nonulcer tissues (P<0.05). H.
pylori-infected gastric ulcers had even higher MMP-7, MMP-9, and TIMP-1 expressions in epithelial cells than NSAID-related
gastric ulcers (P<0.05). In patients with the two combined factors, gastric ulcers expressed similar proportions of antral ulcers
and MMP-7 and MMP-9 intensities to NSAID-related gastric ulcers, but lower MMP-9 and TIMP-1 than H. pylori-infected gastric
ulcers (P<0.05). Conclusions. H. pylori-infected gastric ulcers express higher MMP-7, MMP-9, and TIMP-1 than NSAID-related
ulcers. In patients with the two combined factors, ulcer location and MMP-7 and MMP-9 intensities are similar to NSAID use.
1.Introduction
Helicobacter pylori (H. pylori) infection and nonsteroidal
anti-inﬂammatory drug (NSAID) use are the two most
important causes of gastric ulcers but their clinical courses
are somewhat diﬀerent [1]. In non-NSAID users, H. pylori
eradication enhances peptic ulcer healing [2]. However,
among NSAID users, gastric ulcer healing becomes slower in
H. pylori-eradicated or negative patients than in H. pylori-
infected patients [3, 4]. This implies that there should be
diﬀerent local expression of molecules involved in gastric
ulcer healing between H. pylori-infected and NSAID-related
cases.
Gastric ulcer healing is assisted by the development of
granulation tissues and remodeling at the ulcer base [5].
Matrix metalloproteinases (MMPs) play major roles in
ulcer tissue remodeling and are inhibited by tissue-derived
inhibitors like the tissue inhibitor of matrix metallopro-
teinases (TIMPs) [6, 7]. Recently, several studies have shown
that MMP expression can be regulated by either H. pylori
infection or by NSAID use [8–18]. However, these data are
mostly derived from animal settings, and human clinical
data remains rare, especially in assessing MMP expression
in gastric ulcers among patients with combined H. pylori
infection and NSAID use.2 The Scientiﬁc World Journal
Accordingly, this prospective study aimed to determine if
speciﬁc MMP and TIMP expressions are upregulated in gas-
tric ulcer tissues and if there are diﬀerent MMP expressions
among patients with H. pylori infection, NSAID use, or both
in vivo (in human gastric tissues). The study also aimed to
determine if MMP-9 and TIMP-1 expression levels in gastric
ulcers could be rational markers for identifying patients who
could potentially beneﬁt from H. pylori eradication without
interference or accelerating gastric ulcer healing in patients
with combined H. pylori infection and NSAID use.
2. Methods
2.1. Patients and Study Design. The hospital’s research and
ethics committee approved the study design, and informed
consent was obtained from all participants prior to enroll-
ment. Patients who received upper gastroscopy for melena,
hematochezia, hematemesis, or dyspepsia, and those with
active gastric ulcers, were identiﬁed and consecutively en-
rolled. Patients were excluded if they had tumor or
ulcer bleeding because of mechanical factors (i.e., gastros-
tomy tube induction), bleeding diathesis, or hematological
disorders, such as idiopathic thrombocytopenia, aspirin
use, clopidogrel, warfarin, or cyclooxygenase-2 selective
inhibitors (i.e., celecoxib, etoricoxib). Because of etiologic
heterogeneity, patients who were neither H. pylori infected
nor NSAID users were also excluded.
Gastric mucosal biopsies were obtained under direct
vision gastroscopy (GIF-XQ 260 Endoscope, Olympus Med-
ical Systems Co., Ltd, Tokyo, Japan) using standard biopsy
forceps (Olympus FB-25K-1). Eight biopsies were taken
during each gastroscopic session, including six from the edge
ofulcertissuesandtwofromthenonulceratedantralmucosa
at least 2cm from the ulcer as nonulcer tissues [19].
Patients were diagnosed with H. pylori infection either by
positive rapid urease test (CLO test, Kimberly-Clark, Draper,
Utah, USA) or histologically [19, 20]. The H. pylori-infected
group was deﬁned as having positive test for H. pylori and
without history of NSAID, aspirin, analgesic, or traditional
Chinese medicine use within four weeks before enrollment.
The NSAID-related group was deﬁned as continuous or
sporadic use of nonselective NSAIDs more than three times
per week during the past four weeks and a negative test for
H. pylori. The combined H. pylori-infection and NSAID-use
group was deﬁned as having a positive test for H. pylori and
a history of NSAID use deﬁned as the NSAID-related group.
2.2. Immunohistochemistry Studies for Gastric MMP and
TIMP-1 Expressions. Tissue immunohistochemical staining
was performed using mouse monoclonal antibodies of anti-
human-MMP-3, -7, -9, or TIMP-1 (Chemicon International,
Inc., Temecula, CA, USA). The gastric tissue was ﬁxed in
10% buﬀered formalin, embedded in paraﬃn, and serially
sectioned at 4μm thickness. To stop endogenous peroxidase
activity, the specimen was immersed for 20mins in 3%
hydrogen peroxide and then pretreated with Dako Cytoma-
tion Target Retrieval Solution (Dako, Carpinteria, CA, USA)
forantigen retrieval. The nonspeciﬁc binding sites were satu-
rated with diluted normal blocking serum.
The tissue section was treated with primary antibody
against MMP-3, -7, -9 or TIMP-1 at a dilution of 1:1000
and then incubated overnight in a humidiﬁed chamber at
4◦C. The Vectastain Elite ABC Kit (Vector Laboratories,
Inc., Burlingame, CA, USA) was used for blocking, linkage,
and labeling for staining according to the manufacturer’s
instructions. The Dako Cytomation Liquid DAB + Substrate
Chromogen system was used as chromogen. The section was
then counterstained with hematoxylin. Colon ulcer tissue
was used as positive control.
The same pathologist blinded to patients’ background
scored the staining of MMPs and TIMP-1. The expression
grades of MMP-7, MMP-9, and TIMP-1 in the superﬁcial
epithelium or MMP-3 and TIMP-1 in inﬂammatory cells of
the lamina propria were scored as the percentage of positive-
stained cells. The score ranged from 0–4, as 0 (negative),
1( <5% cells), 2 (5%–29% cells), 3 (30%–59% cells), and
4( ≥60% cells) as before [21, 22]. Otherwise, MMP-9
expression in inﬂammatory cells of the lamina propria was
scored as 0 (no expression), 1 (<5 cells/high power ﬁeld
[HPF]), 2 (5–10 cells/HPF), 3 (11–20 cells/HPF), and 4 (>20
cells/HPF).
2.3. Statistical Analysis. The Pearson’s χ2 test and one-way
analysisofvariance(ANOVA)wereusedtocomparemultiple
groups, while Tukey’s least signiﬁcant diﬀerence test was
used to identify statistically signiﬁcant groups. The Wilcoxon
signed-rank test was used to compare the diﬀerences of
MMP-3, -7, and -9 or TIMP-1 expression between “ulcer
tissues” and “nonulcer tissues”. The Mann-Whitney U test
was applied to assess MMP or TIMP-1 intensity in gastric
tissues between diﬀerent study groups. The diagnostic value
of MMP-9 and TIMP-1 expression in gastric ulcer tissues
for detecting H. pylori infection was measured using the
following three criteria: sensitivity, speciﬁcity, and likelihood
ratios. The receiver operating characteristic (ROC) curves
for determining MMP and TIMP-1 expression cut-oﬀ values
that best discriminated between H. pylori-infected and
NSAID-related gastric ulcers were derived by plotting the
sensitivity versus 1 minus the speciﬁcity for each MMP and
TIMP-1 expression value. The optimal cut-oﬀ point was
deﬁned as the closest point on the receiver operating
characteristic curve to the point at a 1 minus speciﬁcity of
zero and a sensitivity of 100%. All of the tests were two-tailed
and the statistical signiﬁcance was deﬁned as P<0.05.
3. Results
3.1. Demographic Features of the Study Patients. The study
prospectivelyidentiﬁed126(50womenand76men)patients
with active gastric ulcers. Their mean age was 65.4 years. The
gastric ulcer groups included 46 (36.5%) as H. pylori-related
infections, 30 (23.8%) as NSAID users, and 50 (39.7%) with
combined H. pylori infection and NSAID exposure. There
was a signiﬁcant diﬀerence in ulcer location and female
proportion between the three study groups (Table 1). TheThe Scientiﬁc World Journal 3
Table 1: Demographic and clinical characteristics of the three gastric ulcer groups.
Ulcer groups
Parameters H. pylori infected
(n = 46)
NSAID related
(n = 30)
Combined H. pylori infection and
NSAID use (n = 50) P value
Mean age (years) 62.2 (16.6) 64.1 (14.4) 69.2 (13.1) 0.06†
Women (%) 23.9 56.7 44.0 0.01‡
Size of ulcer (cm) 1.4 (1.0) 1.3 (1.1) 1.7 (1.5) 0.20†
Number of ulcers (n), single: multiple 18:28 7:23 12:38 0.19‡
Ulcer locations (n) antrum: corpus: both 21:16: 9 21:1: 8 33:4: 13 0.002‡
Hemoglobin (g/dL) 10.9 (2.8) 9.5 (2.9) 10.1 (2.9) 0.13†
Albumin (g/dL) 3.5 (0.8) 3.7 (0.8) 3.5 (0.6) 0.60†
Creatinine (mg/dL) 1.5 (1.6) 1.6 (1.9) 1.3 (1.1) 0.69†
†Mean (SD or standard deviation), by one-way ANOVA test.
‡The chi-square test. Normal range, Hemoglobin 13.5–17g/dL; Albumin 3–5g/dL; Creatinine 0.7–1.5mg/dL.
H. pylori: Helicobacter pylori; NSAID: Nonsteroidal anti-inﬂammatory drugs.
H. pylori-infected group had higher corpus ulcer tendency
than the other two groups (34.8% versus 3.3% or 8.0%,
resp., P = 0.002). The NSAID-related group had higher
femaleproportion (56.7%versus23.9%or44.0%, P = 0.01).
Otherwise, there was no diﬀerence in the demographic
background and other clinical characteristics among the
three gastric ulcer groups (P>0.05).
3.2. Higher MMP-3, -7, and -9 and TIMP-1 Expressions
in Ulcer Tissues. Over gastric tissues, MMP-7, MMP-9,
and TIMP-1 were positively stained in epithelial cells and
MMP-3, MMP-9, and TIMP-1 in inﬂammatory cells of
the lamina propria (Figure 1). Moreover, in the H. pylori-
infected group, MMP-9 and TIMP-1 expressions over the
superﬁcial epithelium (Figure 2) and MMP-9 expression
over inﬂammatory cells of the lamina propria (Figure 3)o f
gastric ulcer tissues were higher than in nonulcer tissues,
respectively.IntheNSAID-relatedgroup,MMP-9expression
over the superﬁcial epithelium of ulcer tissues was higher
than that in nonulcer tissues (Figure 2). Moreover, in the
NSAID-related group and the combined H. pylori-infection
and NSAID-use group, MMP-3, MMP-9, and TIMP-1
expression over inﬂammatory cells of the lamina propria of
ulcer tissues were higher than in nonulcer tissues (Figure 3)
(P<0.05).
MMP-7, MMP-9, and TIMP-1 expressions over the
superﬁcial epithelium of gastric ulcer tissues were higher
than in nonulcer tissues (P<0.05). MMP-3, MMP-9, and
TIMP-1 expressions over inﬂammatory cells of the gastric
ulcer lamina propria were also higher than in nonulcer
tissues (P<0.001) (Table 2).
3.3. Diﬀerent MMP and TIMP-1 Expressions over Gastric
Tissues among the Study Groups. In nonulcer tissues, MMP-
3,-7,and-9andTIMP-1expressionsweresigniﬁcantlylower
intheNSAID-relatedgroupthaninH.pylori-infectedgroup,
eitheroverthesuperﬁcialepitheliumorinﬂammatorycellsof
the lamina propria (P<0.05) (Figures 2 and 3). The MMP
and TIMP-1 expressions in the combined H. pylori-infection
and NSAID-use group were between the other groups.
Over superﬁcial epithelium of gastric ulcer tissues,
MMP-7, MMP-9, and TIMP-1 expressions were signiﬁcantly
lower in the NSAID-related group than in the H. pylori-
infected group (P<0.05). Moreover, MMP-9 and TIMP-1
expressions were lower in the combined H. pylori-infection
and NSAID-use group than in the H. pylori-infected group
(P<0.05). However, there were similar MMP-7 and MMP-9
expressions between the H. pylori-infected NSAID users and
the noninfected NSAID users (P>0.05) (Figure 2). Over
inﬂammatory cells of the gastric ulcer lamina propria, only
MMP-9 expression (not MMP-3 and TIMP-1) was signif-
icantly higher in the H. pylori-infected group than in the
other two NSAID-use groups with or without H. pylori
infection (P<0.001) (Figure 3).
In ulcer tissues, MMP and TIMP-1 expressions were
similar between diﬀerent gender or between diﬀerent ulcer
locations (Female versus male in the superﬁcial epithelium:
MMP-7, P = 0.46; MMP-9, P = 0.11; TIMP-1, P = 0.34; in
inﬂammatory cells of the lamina propria: MMP-3, P = 0.96;
MMP-9, P = 0.60; TIMP-1, P = 0.26; Antrum versus corpus
versus both in the superﬁcial epithelium: MMP-7, P = 0.23;
MMP-9, P = 0.30; TIMP-1, P = 0.21; in inﬂammatory cells
of the lamina propria: MMP-3, P = 0.64; MMP-9, P = 0.58;
TIMP-1, P = 0.41).
3.4. Prediction of Ulcer Etiology in the Combined H. pylori-
Infected and NSAID-Use Group. The cut-oﬀ values assessed
by ROC curves to deﬁne the optimal diagnostic accuracy of
“H. pylori-infected” ulcer were 2.5 for MMP-9 (area of ROC
curve [AUC] 0.68, 95% CI: 0.56–0.81, P = 0.007) and 1.5
for TIMP-1 (AUC 0.74, 95% CI: 0.63–0.85, P = 0.001) over
gastric ulcer epithelial cells, respectively. The cut-oﬀ point as
3.5 of MMP-9 over the inﬂammatory cells of the gastric
ulcer lamina propria also achieved signiﬁcant AUC as 0.69
(95% CI: 0.56–0.81, P = 0.007). Gastric ulcer tissues with
a combined pattern of MMP-9 ≥3a n dT I M P - 1≥2i nu l c e r4 The Scientiﬁc World Journal
M
M
P
-
3
M
M
P
-
7
M
M
P
-
9
T
I
M
P
-
1
-infected
group
NSAID-related
Combined
and NSAID-related group group
H.pylori -infected H.pylori
Figure 1: The immunohistochemical stains for matrix metalloproteinase (MMP)-3, -7, and -9 and tissue inhibitor of matrix
metalloproteinase (TIMP)-1 in the Helicobacter pylori- (H. pylori-) infected group, in the nonsteroidal anti-inﬂammatory drug- (NSAID-)
related group, and in the combined H. pylori-infection and NSAID-use group, in superﬁcial epithelial cells and inﬂammatory cells of the
lamina propria of gastric tissues (600x). H. pylori-infected gastric ulcers express higher MMP-7, MMP-9, and TIMP-1 than NSAID-related
ulcers. Arrows indicate positive staining.
epithelial cells and MMP-9 ≥ 4 in the ulcer inﬂammatory
cellssigniﬁcantlydeﬁnedthe“H.pylori-relatedulcerpattern”
(AUC 0.67, 95% CI: 0.55–0.79, P = 0.011). Only 10% (5/50)
of ulcer tissues of H. pylori-infected NSAID users expressed
an “H. pylori-related ulcer pattern”.
4. Discussion
This study demonstrates that MMP-3, -7 and -9 and TIMP-1
may play a potential role in gastric ulcer formation or the
healing process. The ﬁndings indicate that H. pylori-infectedThe Scientiﬁc World Journal 5
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Figure 2: Box plots of the distributions and median scores of MMP-7, and -9 and TIMP-1 in the superﬁcial epithelium of gastric ulcer
tissues and nonulcer tissues in diﬀerent groups, respectively. The P values compared scores according to patients in the H. pylori-infected,
NSAID-related, and combined H. pylori-infection and NSAID-use groups by Mann-Whitney U test, and also compared scores according to
ulcer tissues and nonulcer tissues by Wilcoxon signed-rank test. In the box plots, the 75th and 25th percentiles are represented by the top
and bottom of the box, respectively. The horizontal lines refer to the medians. Abbreviations are as in Figure 1.
gastric ulcers express higher MMP-7, MMP-9, and TIMP-1
compared to NSAID-related ulcers. Moreover, in patients
with these two combined factors, MMP-7 and MMP-9
intensities are similar to NSAID use. The data is particularly
important as it supports the hypothesis that ulcer character-
istics in H. pylori-infected NSAID users are mainly similar to
NSAIDexposureratherthanH.pyloriinfection.Accordingly,
this study supports the tentative clinical suggestion of
treatinggastriculcerﬁrstforNSAIDusers,irrespectivetothe
presence of H. pylori infection.
In human stomachs, MMPs and TIMPs are expressed
normally or are upregulated during epithelial regeneration
or tissue remodeling [9, 23–26]. By comparing gastric ulcer
and nonulcer tissues within the same individual, this study
is highly original in revealing how MMP-3, -7, and -9 and
TIMP-1expressionsareupregulatedingastriculcersinduced
by H. pylori infection and NSAID use, respectively (P<0.05;
Table 2, Figures 2 and 3). Because of the dual roles of
MMPs and TIMPs in the process of either ulcer formation or
healing, it is important to study MMP and TIMP expressions
in diﬀerent gastric ulcer etiology.
Previous studies have shown that H. pylori infections
induce MMP-7 and MMP-9 expressions via activation of
nuclear factor kappa light-chain enhancer of activated B cells6 The Scientiﬁc World Journal
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Figure 3: Box plots of the distributions and median scores of MMP-3, MMP-9, and TIMP-1 in inﬂammatory cells of the lamina propria
of gastric ulcer tissues and nonulcer tissues in diﬀerent groups, respectively. The P values compared scores according to patients in the
H. pylori-infected, NSAID-related, and combined H. pylori-infection and NSAID-use groups by Mann-Whitney U test and also compared
scores according to ulcer tissues and nonulcer tissues by Wilcoxon signed-rank test. In the box plots, the 75th and 25th percentiles are
represented by the top and bottom of the box, respectively. The horizontal lines refer to the medians. Abbreviations are as in Figure 1.
(NF-κB) [15]. However, NSAIDs inhibit tumor necrosis
factor- (TNF-) induced NF-κBa c t i v a t i o n[ 27]. Because NF-
κB and MMPs play a relevant role in the processes of ulcer
healing, blocking NF-κB activation may result in impaired
ulcer repair [28]. H. pylori infection is also associated with
upregulation of TIMP-1 [18]. The current study validates
that MMP-7, MMP-9, and TIMP-1 expressions are signiﬁ-
cantly higher in H. pylori-infected patients than in NSAID
users (P<0.05) (Figures 2 and 3). These data partly explain
why longer healing is required in the NSAID-related ulcers
than in the H. pylori-infected ulcers [15].
TIMP-1 is expressed strongly in epithelial cells and
weakly in inﬂammatory cells in H. pylori-infected gastric
mucosa, but absent in uninfected subjects [18]. In our study,
Figures 2 and 3 showed that in nonulcer tissue, the H. pylori-
infected group has higher TIMP-1 expression than in the
NSAID-related group either in the superﬁcial epithelium or
in inﬂammatory cells (P = 0.001). However, in ulcer tissues,
inﬂammatory cells had higher TIMP-1 upregulation than
in nonulcer tissues, especially in the NSAID-related group
and in the combined H. pylori-infection and NSAID-use
group (P = 0.009 and 0.005, resp., Figure 3). TIMP-1 is
an endogenous MMP inhibitor produced by the same cells
which express MMPs [9, 26]. In addition, the upregulation
of MMP-3 in inﬂammatory cells of ulcer tissues is similar
to TIMP-1 (Figure 3). We proposed that inﬂammatory cells
of gastric ulcers participate vigorously in the healing proc-
ess and upregulate MMP-3 and TIMP-1 strongly either inThe Scientiﬁc World Journal 7
Table 2: The distributions of MMP-3, -7, and -9 and TIMP-1 net over diﬀerent histologic locations of gastric ulcer tissues compared to
non-ulcer tissues.
Net increase (n,% ) P o s i t i v e E q u a l N e g a t i v e P † value
Superﬁcial epithelium
MMP-7 35 (27.8%) 70 (55.5%) 21 (16.7%) 0.023
MMP-9 49 (38.9%) 65 (51.6%) 12 (9.5%) <0.001
TIMP-1 28 (22.2%) 87 (69.1%) 11 (8.7%) 0.005
Inﬂammatory cells of gastric lamina propria
MMP-3 43 (34.1%) 76 (60.3%) 7 (5.6%) <0.001
MMP-9 75 (60.0%) 38 (30.4%) 12 (9.6%) <0.001
TIMP-1 32 (25.4%) 86 (68.3%) 8 (6.3%) <0.001
†P valuesindicatethesigniﬁcantdiﬀerenceofhigherMMP-3,-7,and-9andTIMP-1intensitiesonulcertissuescomparedtoantralnon-ulcertissues(assessed
by Wilcoxon signed-rank test).
MMP: matrix metalloproteinases; TIMP: tissue inhibitor of matrix metalloproteinase.
H. pylori infection or in the other two NSAID-use groups
with or without H. pylori infection (Table 2).
Due to diﬀerent expressions of MMPs and TIMP-1
between H. pylori-infected and NSAID-related gastric ulcers,
cut-oﬀ values of MMPs and TIMP-1 have been measured to
discriminate the possible characteristics: H. pylori infection
or NSAID use? The results show stronger patterns of
MMP-9 and TIMP-1 expression in H. pylori-infected gastric
ulcer tissues. As such, in most (45/50, 90%) patients with
combined H. pylori-infection and NSAID-use ulcers, it is
possible that NSAID-induced gastropathy rather than H.
pyloriinfectionistheprincipalcharacteristic.Inaddition,the
current study also shows that H. pylori-infected gastric ulcers
have corpus predilection compared to NSAID-related ulcers
with or without H. pylori infection. This is compatible with
ﬁndings by Al-Assi et al. (Table 1)[ 29].
Our results showed that combined H. pylori-infection
and NSAID-use ulcers are similar to NSAID-related ulcers
but are diﬀerent from H. pylori-infected ulcers. The reason
why combined H. pylori-infection and NSAID-use ulcers
were similar to NSAID-induced gastropathy cannot be fully
ascertained. We proposed that NSAIDs inhibit TNF-induced
NF-κB activation and downregulate MMP-7 and MMP-9
expressions induced by H. pylori infection. Nevertheless,
this may be the reason why eradicating H. pylori does not
enhance gastric ulcer healing in such patients [3, 4]. Based
onthetranslationevidenceofthisstudy,treatingsuchgastric
ulcers with proton-pump inhibitors ﬁrst may not eradicate
H. pylori before ulcer healing but result in H. pylori-induced
cyclooxygenase-2 and MMP-9 upregulation. This may also
potentiate the inhibition eﬀect of omeprazole on gastric acid
secretion [15, 28, 30–32].
Previous study showed MMP-1 concentration is sig-
niﬁcantly higher in H. pylori-induced ulcers compared to
NSAID-induced ones [33]. Our study further validated the
diﬀerence of MMP-9 and TIMP-1 expression on the ulcer
etiology. More importantly, our study showed that the
possible major cause of ulcerogenesis in combined H. pylori-
infection and NSAID-use ulcers is favored to be NSAID-
related rather than H. pylori induced. In this study, we
did not investigate MMP-2 and TIMP-2 expression because
MMP-2 in H. pylori infection and indomethacin treatment
has limited signiﬁcance [15, 17, 34, 35]. Moreover, TIMP-2
appears to be designed speciﬁcally to interact with MMP-
2[ 36]. On the other hand, it will be interested to compare
MMP and TIMP-1 expressions in the middle or ﬁnal stage
of the healing process between H. pylori-infected ulcers and
NSAID-related ulcers.
In summary, H. pylori-infected gastric ulcers express
higher MMP-9 and TIMP-1 than NSAID-related ulcers.
Based on the predominant ulcer location over the antrum
and the weaker MMP-9 and TIMP-1 expressions in gastric
ulcer tissues, gastric ulcers in H. pylori-infected NSAID users
may be predominantly similar to those in NSAID use. As
such, ulcer healing should be the ﬁrst management objective,
followed by H. pylori later, in cases of ulcers concurrent with
H. pylori infection and NSAID exposure.
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